Page last updated: 2024-08-23

pirfenidone and Pulmonary Fibrosis

pirfenidone has been researched along with Pulmonary Fibrosis in 125 studies

Research

Studies (125)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (6.40)	18.2507
2000's	31 (24.80)	29.6817
2010's	62 (49.60)	24.3611
2020's	24 (19.20)	2.80

Authors

Authors	Studies
Cao, X; Gao, S; Guo, Y; Huang, M; Li, X; Liu, S; Xie, C; Zhai, Y; Zhou, H	1
Comes, A; Lerede, M; Richeldi, L; Sgalla, G	1
Abdelaziz, A; Dutta, P; Finnerty, JP; Kamil, H; Ponnuswamy, A	1
Fares, N; Habr, B; Hajal, J; Layoun, H; Saliba, Y; Smayra, V	1
Jiao, Y; Tan, Y; Tang, X; Wang, D; Yong, C; Zhang, R	1
Al-Gareeb, AI; Al-Kuraishy, HM; Batiha, GE; Faidah, H; Saad, HM; Simal-Gandara, J	1
Bo, C; Jia, Q; Li, M; Tang, Q; Xing, C; Zhang, Z	1
Adnot, S; Bischof, O; Lipskaia, L	1
Gower, WA; Hagood, JS; McKinzie, CJ; Vece, TJ	1
Bai, C; Charalampidis, C; Hohenforst-Schmidt, W; Huang, H; Kosmidis, C; Kougkas, N; Matthaios, D; Nikolaou, C; Oikonomou, P; Papadopoulos, V; Perdikouri, EI; Petanidis, S; Petridis, D; Sardeli, C; Zarogoulidis, P	1
Distler, J; Fischer, A	1
Axmann, J; Corte, TJ; Cottin, V; Fischer, A; Gilberg, F; Kirchgaessler, KU; Kreuter, M; Lederer, DJ; Maher, TM; Molina-Molina, M; Samara, K	1
Eichinger, M; Heussel, CP; Kahn, N; Kreuter, M; Lars, K; Palmucci, S; Polke, M; Sambataro, D; Sambataro, FM; Sambataro, G; Sarmand, N; Torrisi, SE; Vancheri, C; Wälscher, J	1
Dai, Y; Huang, X; Lv, Q; Ruan, Z; Wang, J; Xu, C	1
Fellrath, JM	1
Condos, R; Deshwal, H; Gibson, CD; Kugler, MC; Munger, JS	1
Ferrara, F; Granata, G; La Porta, R; Pelliccia, C; Vitiello, A	1
Kolb, MRJ; Scallan, C; Wongkarnjana, A	1
Hu, Z; Li, K; Lv, X	1
Banerjee, S; Cui, H; Dey, T; Ge, J; Jiang, D; Liu, G; Liu, RM; Matthews, QL; Xie, N	1
Li, JW; Tan, K; Wang, GQ; Wu, Z; Yang, W; Zhang, C; Zhao, H	1
Li, SQ; Zou, H	1
Chen, TH; Chu, KA; Fu, YS; Hsu, CW; Kuo, FH; Lin, WR; Yeh, CC	1
Altinisik, G; Karasu, U; Ufuk, F	1
Behr, J; Blaas, S; Bonella, F; Bonnet, R; Claussen, M; Ficker, JH; Frankenberger, M; Freise, J; Grohe, C; Günther, A; Hammerl, P; Held, M; Hummler, S; Johow, J; Kahn, N; Kneidinger, N; Koschel, D; Kreuter, M; Neumeister, W; Neuser, P; Prasse, A; Rabe, KF; Schönfeld, N; Tello, S; Welte, T; Wilkens, H; Wirtz, H	1
Bari, E; Corsico, AG; Ferrarotti, I; Perteghella, S; Richeldi, L; Saracino, L; Torre, ML	1
Homma, S; Isshiki, T; Kishi, K; Miyoshi, S; Nakamura, Y; Sakamoto, S; Shimizu, H; Yamasaki, A	1
Kang, L; Liu, Y; Lu, F; Wang, Y; Wang, Z	1
Kitamura, H; Ogura, T	1
Araya, J; Asano, H; Fujita, Y; Hara, H; Hashimoto, M; Ichikawa, A; Ishikawa, T; Ito, S; Kadota, T; Kaneko, Y; Kobayashi, K; Kurita, Y; Kuwano, K; Minagawa, S; Morikawa, T; Nakayama, K; Numata, T; Odaka, M; Saito, N; Sato, N; Tsubouchi, K; Utsumi, H; Wakui, H; Yamashita, M; Yanagisawa, H; Yoshida, M; Yoshii, Y	1
Bahudhanapati, H; Kass, DJ	1
Mandegary, A; Pardakhty, A; Rajaian, H; Rasooli, R	1
Arakawa, H; Fujiu, K; Hase, I; Ishii, Y; Miyamoto, H; Sakuma, H; Takizawa, H; Yamaguchi, B	1
Behr, J; Günther, A; Kreuter, M; Neuser, P; Prasse, A; Rabe, K; Schade-Brittinger, C; Wagner, J	1
Kamali, Y; Mandegary, A; Nabipour, F; Pourgholamhosein, F; Rasooli, R	1
Ghazi-Khansari, M; Heidari, MR; Iranpour, M; Mandegary, A; Pourgholamhossein, F; Pourgholi, L; Pournamdari, M; Poursalehi, HR; Rasooli, R; Samareh-Fekri, M	1
Chen, Z; Li, XJ; Liao, XP; Lin, H; Xiao, H; Zhang, GF; Zhang, J; Zhang, X	1
Borie, R; Cadranel, J; Cottin, V; Crestani, B; Gamez, AS; Gondouin, A; Justet, A; Kannengiesser, C; Magois, E; Manali, E; Marchand-Adam, S; Molina Molina, M; Nunes, H; Papiris, S; Prevot, G; Reynaud-Gaubert, M; Thabut, G; Tromeur, C; Wemeau, L	1
Asmani, M; Chen, Z; Hinz, B; Hsia, I; Li, Y; Velumani, S; Wawrzyniak, N; Zhao, R	1
Ask, K; Bellaye, PS; Gauldie, J; Granton, E; Hambly, N; Iglarz, M; Imani, J; Kolb, M; Sato, S; Shimbori, C; Upagupta, C; Yanagihara, T	1
Li, L; Liu, B; Qin, W; Tang, Y; Wu, B; Yi, M; Yuan, X	1
Dupont, LJ; Gheysens, O; Godinas, L; Goffin, KE; Heigl, T; McDonough, JE; Neyrinck, AP; Sacreas, A; Schaevers, V; Van Herck, A; Van Raemdonck, DE; Vanaudenaerde, BM; Verbeken, EK; Verleden, GM; Verleden, SE; Vos, R; Wuyts, WA; Yserbyt, J	1
Akal, O; Akal, T; Barbu, A; Gahl, WA; Gochuico, BR; Introne, WJ; McGowan, MP; Merideth, MA; O'Brien, KJ; Seward, SL	1
Bo, C; Guo, J; Jia, Q; Shao, H; Yang, Z; Zhang, Z	1
Agouni, A; Carru, C; Cossu, A; Fois, AG; Giordo, R; Pintus, G; Pirina, P; Posadino, AM; Rizk, NM; Zinellu, A	1
Drummer, OH; Pope, JD; Schneider, HG	1
Bergna, M; de Andrade, J; Falk, J; Hallowell, R; Jouneau, S; Kondoh, Y; Morrow, L; Randerath, W; Richeldi, L; Strek, M; Tabaj, G; Varone, F	1
Cottin, V; Fischer, A; Harari, S; Quaresma, M; Stowasser, S; Wollin, L	1
Li, SM; Liang, SS; Lin, Y	1
Lin, H; Wu, C; Zhang, X	1
Aoki, Y; Kato, M; Kojo, Y; Onoue, S; Seto, Y; Yamada, S	1
Onoue, S; Yamada, S	1
De Jong, PA; De Raedt, N; Dupont, LJ; Gheysens, O; Ruttens, D; Van Raemdonck, DE; Vanaudenaerde, BM; Vandermeulen, E; Verleden, GM; Verleden, SE; Vos, R; Yserbyt, J	1
Azuma, A; Fujita, K; Gemma, A; Hayashi, H; Inomata, M; Kamio, K; Kokuho, N; Matsuda, K; Miura, Y; Nei, T; Saito, Y	1
Eder, I; Goldscheider, I; Przybilla, B; Reinholz, M; Ruëff, F; Ruzicka, T; Schauber, J; Schaumann, A; Varga, R; Wollenberg, A; Wulffen, W	1
Hara, S; Harada, T; Ishimatsu, Y; Kakugawa, T; Kawabata, Y; Kohno, S; Miura, S; Mukae, H; Nakashima, S; Sakamoto, N; Tomonaga, M; Yoshii, C	1
Diso, D; Frati, G; Ialleni, E; Ialongo, P; Paone, G; Peruzzi, M; Quagliarini, F; Rose, D; Sebastiani, A; Venuta, F	1
Álvarez-Sala Walther, R; Gómez Carrera, L	1
Armendariz-Borunda, J; Lopez-de la Mora, DA; Lucano-Landeros, S; Macias-Barragan, J; Montoya-Buelna, M; Sanchez-Enriquez, S; Sanchez-Roque, C	1
Furlow, B	1
Caruana, DM; Wylie, G	1
Kapp, A; Papakonstantinou, E; Prasse, A; Raap, U; Schacht, V	1
Bacon, KB; Boehme, SA; DiTirro, DN; Franz-Bacon, K; Ly, TW	1
Azuma, A	2
Roman, J; Santiago-Cornier, A; Vergne, Y; Vicary, GW; Young, LR	1
Alexander, KA; Antin, JH; Blazar, BR; Cutler, CS; Du, J; Flynn, R; Hill, GR; Koreth, J; Lineburg, KE; Loschi, M; Luznik, L; MacDonald, KP; Maillard, I; Meng, J; Miklos, D; Panoskaltsis-Mortari, A; Paz, K; Ritz, J; Robinson, TM; Roy, S; Schacker, TW; Serody, JS; Vulic, A	1
Bai, Y; Deng, F; Feng, J; Liang, L; Liu, X	1
Aljama-Corrales, T; Castaneda-Villa, N; Charleston-Villalobos, S; Gonzalez-Camarena, R; Mateos-Toledo, H; Mejia-Avila, M	1
Arimura, A; Hikita, I; Kawabata, T; Matsushima, S; Nagira, M; Oku, H; Shimizu, T; Torii, M; Ueyama, A	1
Maher, TM; Wells, AU	1
Rabin, DU; Scriabine, A	1
Gomer, RH; Lupher, ML	1
Balduzzi, S; Cerri, S; D'Amico, R; Del Giovane, C; Luppi, F; Richeldi, L; Spagnolo, P; Walters, EH	1
Chen, JQ; Chen, RP; Feng, LF; Jia, ZY; Jiang, ZQ; Ju, L; Ma, Z; Zhang, X; Zhu, LJ	1
Bernardini, I; Cardona, H; Gahl, WA; Gochuico, BR; Hess, R; Markello, TC; O'Brien, K; Salas, J; Troendle, J; Yao, J	1
Celik, G; Ciledağ, A; Cirit Koçer, B; Kaya, A; Köktürk, N; Numanoğlu, N	1
Hu, GX; Li, JW; Lu, ZQ; Shen, XW; Sun, W; Tong, SH; Xiao, M; Yu, XC	1
Kossen, K; Pan, L; Ruhrmund, DW; Schaefer, CJ; Seiwert, SD	1
Cagnon, L; Duboux, G; Fioraso-Cartier, L; Gaggini, F; Gradia, A; Heitz, F; Houngninou-Molango, S; Laleu, B; Merlot, C; Orchard, M; Page, P; Szyndralewiez, C	1
Hodgson, U; Kaarteenaho, R; Myllärniemi, M	1
Azuma, A; Miyazaki, Y; Mizushima, T; Sato, K; Tanaka, KI	1
Fujita, H; Hara, S; Hisatomi, K; Ishimatsu, Y; Kakugawa, T; Kohno, S; Kubota, H; Mukae, H; Nagata, K; Nakamichi, S; Oku, H; Sakamoto, N; Urata, Y	1
Jenkins, G; Laurent, G; Ntolios, P; Sivakumar, P	1
Abbasi, H; Aran, S; Ghaffari, A; Keshavarz, A; Seifirad, S; Taslimi, S	1
Huang, H; Jiang, C; Liu, J; Lu, Z; Wang, Y; Xu, Z	1
Kompella, UB; Redente, EF; Riches, DW; Thakur, A; Trivedi, R	1
Lota, HK; Wells, AU	1
Avila, NA; Brantly, M; Calis, KA; Cardona, H; Gahl, WA; Gochuico, B; Montalvo, C; Padua, A; Troendle, J	1
Selman, M	1
Cottin, V	1
Hamada, K; Izumi, T; Nagai, S; Shigematsu, M; Taniyama, M; Yamauchi, S	1
Brien, JF; Card, JW; Margolin, SB; Massey, TE; Racz, WJ	1
Flaherty, KR; Lynch, JP; Martinez, FJ; Thannickal, VJ	1
Abe, K; Fujii, T; Hayashi, T; Ishii, H; Kadota, J; Kakugawa, T; Kohno, S; Miyazaki, M; Mukae, H; Oku, H	1
Abe, S; Azuma, A; Itoh, H; Kudoh, S; Nagai, S; Nakata, K; Nukiwa, T; Ohi, M; Sato, A; Suga, M; Taguchi, Y; Tsuboi, E	1
du Bois, RM	1
Cheng, Y; Drew, P; Gaugler, AC; Liu, H; Visner, GA	1
Liu, A; Troendle, JF; Wu, C; Yu, KF	1
Gould, MK; Levitt, J	1
Mathai, SC; Polito, AJ	1
Antoniu, SA	2
Nathan, SD	1
Eickelberg, O; Günther, A; Markart, P; Seeger, W	1
Allen, J; Baran, CP; Bhatt, N; Magro, C; Marsh, CB	1
Collard, HR; King, TE; Walter, N	1
Ammar, YA; Bayomi, AH; El-Sehrawi, HM; Ismail, MM; Noaman, E; Shawer, TZ	1
Gu, L; Guo, ZJ; Tian, XL; Yao, W; Zhu, YJ	1
Dosanjh, A	1
Chen, H; Shi, S; Wu, J; Zeng, F	1
Ishida, K; Iwanaga, T; Karakawa, T; Kitamado, M; Maruyama, K; Mitani, Y; Muramoto, Y; Nabeshima, T; Nakagawa, K; Sasamoto, K; Sato, K	1
Giri, SN; Hyde, DM; Iyer, SN; Margolin, SB; Schiedt, MJ; Wild, JS	1
Kehrer, JP; Margolin, SB	1
Giri, S; Mansoor, JK; Schelegle, ES	1
Giri, SN; Gurujeyalakshmi, G; Hollinger, MA	1
Giri, SN; Gurujeyalakshmi, G; Iyer, SN	2
Johnson, WC; Lockhart, D; Mageto, Y; Raghu, G	1
Nicod, LP	1
Giri, SN; Hyde, DM; Iyer, SN	1
Millar, AB; Poole, AR; Thickett, DR	1
Lasky, JA; Ortiz, LA	1

Reviews

34 review(s) available for pirfenidone and Pulmonary Fibrosis

Article	Year
COVID-related fibrosis: insights into potential drug targets. Expert opinion on investigational drugs, 2021, Volume: 30, Issue:12 Topics: Animals; Antifibrotic Agents; COVID-19; Critical Illness; Humans; Indoles; Pulmonary Fibrosis; Pyridones	2021
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC pulmonary medicine, 2021, Dec-11, Volume: 21, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrotic Agents; Cause of Death; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pulmonary Fibrosis; Pyridones; Treatment Outcome	2021
Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology, 2022, Volume: 30, Issue:6 Topics: Acute Lung Injury; COVID-19 Drug Treatment; Fibrosis; Goals; Humans; Pulmonary Fibrosis; Respiratory Distress Syndrome; SARS-CoV-2	2022
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clinical rheumatology, 2019, Volume: 38, Issue:10 Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppression Therapy; Indoles; Kaplan-Meier Estimate; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Risk Factors; Tomography, X-Ray Computed	2019
[Antifibrotic therapy and progressive lung fibrosis]. Revue medicale suisse, 2020, Jun-17, Volume: 16, Issue:698 Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pulmonary Fibrosis; Pyridones	2020
Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease. Lung, 2020, Volume: 198, Issue:4 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Vital Capacity	2020
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? European journal of clinical pharmacology, 2020, Volume: 76, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Inflammation; Interleukin-1; Interleukin-6; Pandemics; Pneumonia, Viral; Pulmonary Fibrosis; Pyridones; SARS-CoV-2	2020
Autophagy and Pulmonary Fibrosis. Advances in experimental medicine and biology, 2020, Volume: 1207 Topics: Autophagy; Disease Progression; Humans; Indoles; Pulmonary Fibrosis; Pyridones	2020
Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19. Journal of medical virology, 2021, Volume: 93, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; COVID-19; Humans; Indoles; Lung; Patient Discharge; Pulmonary Fibrosis; Pyridones; Severity of Illness Index; Signal Transduction	2021
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. European respiratory review : an official journal of the European Respiratory Society, 2018, Dec-31, Volume: 27, Issue:150 Topics: Disease Progression; Humans; Indoles; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Risk Factors; Treatment Outcome	2018
Fibrosing interstitial lung diseases: knowns and unknowns. European respiratory review : an official journal of the European Respiratory Society, 2019, Mar-31, Volume: 28, Issue:151 Topics: Disease Progression; Health Status; Humans; Indoles; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Quality of Life; Respiratory System Agents; Risk Factors; Severity of Illness Index; Treatment Outcome	2019
Efficacy of pirfenidone for the treatment of pulmonary fibrosis: An updated systematic review protocol of randomized controlled trial. Medicine, 2019, Volume: 98, Issue:17 Topics: Humans; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Respiratory System Agents; Systematic Reviews as Topic	2019
Pirfenidone. First, do no harm. Prescrire international, 2013, Volume: 22, Issue:138 Topics: Anti-Inflammatory Agents, Non-Steroidal; Heart Diseases; Humans; Pulmonary Fibrosis; Pyridones; Risk Assessment	2013
An autopsy case of Hermansky-Pudlak syndrome: a case report and review of the literature on treatment. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:23 Topics: Adrenal Cortex Hormones; Autopsy; Ceroid; Drug Therapy, Combination; Fatal Outcome; Female; Hemorrhagic Disorders; Hermanski-Pudlak Syndrome; Humans; Immunosuppressive Agents; Lipofuscin; Lung Transplantation; Middle Aged; Pulmonary Fibrosis; Pyridones; Respiratory Insufficiency	2014
Role and New Insights of Pirfenidone in Fibrotic Diseases. International journal of medical sciences, 2015, Volume: 12, Issue:11 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Eye; Fibrosis; Humans; Kidney; Liver Cirrhosis; Myocardium; Pulmonary Fibrosis; Pyridones	2015
Pulmonary Fibrosis in Hermansky-Pudlak Syndrome. Annals of the American Thoracic Society, 2016, Volume: 13, Issue:10 Topics: Animals; Biomarkers; Disease Progression; Hermanski-Pudlak Syndrome; Hispanic or Latino; Humans; Indoles; Lung Transplantation; Membrane Proteins; Mice; Mutation; Puerto Rico; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed	2016
New developments in the therapy of pulmonary fibrosis. Advances in pharmacology (San Diego, Calif.), 2009, Volume: 57 Topics: Animals; Clinical Trials as Topic; Drug Discovery; Humans; Pulmonary Fibrosis; Pyridones	2009
Investigational approaches to therapies for idiopathic pulmonary fibrosis. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Design; Drugs, Investigational; Humans; Pulmonary Fibrosis; Pyridones	2010
Non-steroid agents for idiopathic pulmonary fibrosis. The Cochrane database of systematic reviews, 2010, Sep-08, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colchicine; Cyclophosphamide; Humans; Immunosuppressive Agents; Interferon-gamma; Prednisone; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Recombinant Proteins	2010
Antifibrotic activities of pirfenidone in animal models. European respiratory review : an official journal of the European Respiratory Society, 2011, Volume: 20, Issue:120 Topics: Administration, Oral; Animals; Cardiomyopathies; Disease Models, Animal; Extracellular Matrix Proteins; Humans; Kidney Diseases; Liver Cirrhosis; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta	2011
[Idiopathic pulmonary fibrosis -- progress in sight]. Duodecim; laaketieteellinen aikakauskirja, 2011, Volume: 127, Issue:24 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Finland; Humans; Prevalence; Pulmonary Fibrosis; Pyridones; Registries	2011
Into the matrix: targeting fibroblasts in pulmonary fibrosis. Current opinion in pulmonary medicine, 2012, Volume: 18, Issue:5 Topics: Cytokines; Extracellular Matrix; Fibroblasts; Humans; Intercellular Signaling Peptides and Proteins; Myofibroblasts; Pulmonary Fibrosis; Pyridones; Signal Transduction	2012
Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PloS one, 2012, Volume: 7, Issue:10 Topics: Humans; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic	2012
The evolving pharmacotherapy of pulmonary fibrosis. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:1 Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Interstitial Pneumonias; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Sarcoidosis, Pulmonary; Scleroderma, Systemic; Treatment Outcome	2013
[Treatment of pulmonary fibrosis]. Presse medicale (Paris, France : 1983), 2002, Oct-19, Volume: 31, Issue:34 Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Azathioprine; Colchicine; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Interferon-gamma; Lung; Lung Transplantation; Male; Middle Aged; Oxygen Inhalation Therapy; Pregnancy; Prognosis; Prospective Studies; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Time Factors	2002
Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:8 Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Connective Tissue Growth Factor; Eicosanoids; Endothelin-1; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Interferon-gamma; Molybdenum; Protein Kinase Inhibitors; Proteins; Pulmonary Fibrosis; Pyridones; Recombinant Proteins; Relaxin; Renin-Angiotensin System; Tumor Necrosis Factor-alpha	2004
[Expectation of new treatments for idiopathic interstitial pneumonias]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2005, Volume: 42, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Clinical Trials as Topic; Hermanski-Pudlak Syndrome; Humans; Imatinib Mesylate; Interferon-gamma; Lung; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Pyrimidines; Survival Analysis	2005
Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach. Clinics in chest medicine, 2006, Volume: 27, Issue:1 Suppl 1 Topics: Acetylcysteine; Azathioprine; Benzamides; Bosentan; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Etanercept; Evidence-Based Medicine; Humans; Imatinib Mesylate; Immunoglobulin G; Interferon-gamma; Piperazines; Prednisone; Pulmonary Fibrosis; Pyridones; Pyrimidines; Receptors, Tumor Necrosis Factor; Sulfonamides	2006
[Pulmonary fibrosis--a therapeutic dilemma?]. Medizinische Klinik (Munich, Germany : 1983), 2006, Apr-15, Volume: 101, Issue:4 Topics: Acetylcysteine; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Benzamides; Bosentan; Cyclophosphamide; Drug Therapy, Combination; Etanercept; Free Radical Scavengers; Humans; Imatinib Mesylate; Immunoglobulin G; Immunosuppressive Agents; Interferon-gamma; Lung Transplantation; Piperazines; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Sulfonamides	2006
Promising pharmacologic innovations in treating pulmonary fibrosis. Current opinion in pharmacology, 2006, Volume: 6, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antioxidants; Connective Tissue Growth Factor; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung; Molybdenum; Neovascularization, Pathologic; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic	2006
Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proceedings of the American Thoracic Society, 2006, Volume: 3, Issue:4 Topics: Acetylcysteine; Anticoagulants; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunosuppressive Agents; Interferon-gamma; Lung Transplantation; Prednisone; Pulmonary Fibrosis; Pyridones; Quality of Life; Recombinant Proteins	2006
Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:7 Topics: Administration, Oral; Amiodarone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cell Line; Clinical Trials, Phase II as Topic; Connective Tissue Growth Factor; Cricetinae; Cyclophosphamide; Drug Evaluation, Preclinical; Drugs, Investigational; Fibroblasts; Hermanski-Pudlak Syndrome; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung Transplantation; Mice; Orphan Drug Production; Photosensitivity Disorders; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Transforming Growth Factor beta; Treatment Outcome; Tumor Necrosis Factor-alpha	2006
The balance between collagen synthesis and degradation in diffuse lung disease. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2001, Volume: 18, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biomarkers; Collagen; Disease Models, Animal; Humans; Inflammation; Interferon-gamma; Lung Diseases, Interstitial; Pulmonary Fibrosis; Pyridones	2001
Antifibrotic therapy for the treatment of pulmonary fibrosis. The American journal of the medical sciences, 2001, Volume: 322, Issue:4 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Clinical Trials as Topic; Colchicine; Humans; Interferon Type I; Interferon-gamma; Niacin; Penicillamine; Pulmonary Fibrosis; Pyridones; Recombinant Proteins; Taurine	2001

Trials

9 trial(s) available for pirfenidone and Pulmonary Fibrosis

Article	Year
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2 Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Mycophenolic Acid; Progression-Free Survival; Pulmonary Fibrosis; Pyridones; Respiratory Function Tests; Treatment Outcome; Vital Capacity	2020
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. The Lancet. Respiratory medicine, 2021, Volume: 9, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Early Termination of Clinical Trials; Female; Humans; Intention to Treat Analysis; Lung Diseases, Interstitial; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Respiratory Function Tests; Symptom Assessment	2021
Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC pulmonary medicine, 2017, Sep-06, Volume: 17, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Connective Tissue Diseases; Disease Progression; Double-Blind Method; Female; Humans; Lung; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Research Design; Treatment Outcome; Vital Capacity; Young Adult	2017
Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. Molecular genetics and metabolism, 2011, Volume: 103, Issue:2 Topics: Adult; Female; Hermanski-Pudlak Syndrome; Humans; Male; Middle Aged; Patient Compliance; Pulmonary Fibrosis; Pyridones; Radiography; Treatment Outcome	2011
Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Molecular genetics and metabolism, 2002, Volume: 76, Issue:3 Topics: Adult; Double-Blind Method; Female; Hermanski-Pudlak Syndrome; Humans; Male; Middle Aged; Patient Compliance; Placebos; Pulmonary Fibrosis; Pyridones; Tomography, X-Ray Computed; Treatment Outcome	2002
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine, 2005, May-01, Volume: 171, Issue:9 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Exercise; Exercise Test; Female; Humans; Male; Middle Aged; Oxygen Consumption; Prospective Studies; Pulmonary Fibrosis; Pyridones; Total Lung Capacity; Vital Capacity	2005
Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. Expert opinion on investigational drugs, 2005, Volume: 14, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Pulmonary Diffusing Capacity; Pulmonary Fibrosis; Pyridones; Quality of Life; Total Lung Capacity; Vital Capacity	2005
Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. Journal of clinical pharmacology, 2007, Volume: 47, Issue:10 Topics: Adult; Area Under Curve; China; Female; Food-Drug Interactions; Humans; Male; Pulmonary Fibrosis; Pyridones; Sex Factors	2007
Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. American journal of respiratory and critical care medicine, 1999, Volume: 159, Issue:4 Pt 1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Prospective Studies; Pulmonary Fibrosis; Pulmonary Gas Exchange; Pyridones; Survival Rate; Total Lung Capacity; Vital Capacity	1999

Other Studies

82 other study(ies) available for pirfenidone and Pulmonary Fibrosis

Article	Year
In vitro screening for compounds from Hypericum longistylum with anti-pulmonary fibrosis activity. Bioorganic & medicinal chemistry letters, 2019, 11-15, Volume: 29, Issue:22 Topics: Animals; Antifibrinolytic Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibroblasts; Hypericum; Mice; Molecular Structure; Plant Extracts; Pulmonary Fibrosis; Signal Transduction; Smad3 Protein; Structure-Activity Relationship; Transforming Growth Factor beta1	2019
Pirfenidone mitigates TGF-β1-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model. Cytokine, 2022, Volume: 154 Topics: Animals; Guinea Pigs; Lung; Lung Diseases, Interstitial; Male; Mice; Myositis; Pulmonary Fibrosis; Pyridones; Transforming Growth Factor beta1	2022
Pirfenidone ameliorates early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome by inhibiting endothelial-to-mesenchymal transition via the Hedgehog signaling pathway. International immunopharmacology, 2022, Volume: 109 Topics: Animals; Hedgehog Proteins; Lipopolysaccharides; Pulmonary Fibrosis; Pyridones; Respiratory Distress Syndrome; Signal Transduction	2022
Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways. Ecotoxicology and environmental safety, 2022, Oct-01, Volume: 244 Topics: Animals; Fibrosis; Hydroxyproline; Interleukin-18; Janus Kinase 2; Macrophages; Pneumonia; Pulmonary Fibrosis; Pyridones; Rats; RNA, Messenger; Signal Transduction; Silicosis; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vimentin	2022
What is hidden behind a pulmonary hypertensive, fibrotic and inflammatory phenotype? The European respiratory journal, 2022, Volume: 60, Issue:4 Topics: Animals; Mice; Phenotype; Pulmonary Fibrosis; Pyridones; Scleroderma, Systemic	2022
Use of pirfenidone in pediatric patients with interstitial lung disease and pulmonary fibrosis. Pediatric pulmonology, 2023, Volume: 58, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Diseases, Interstitial; Pulmonary Fibrosis; Pyridones	2023
Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment. Therapeutic delivery, 2023, Volume: 14, Issue:8 Topics: Humans; Nebulizers and Vaporizers; Particle Size; Pulmonary Fibrosis; Respiratory Aerosols and Droplets	2023
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. BMC pulmonary medicine, 2019, Nov-12, Volume: 19, Issue:1 Topics: Aged; Disease Progression; Female; Humans; Indoles; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Phenotype; Pulmonary Fibrosis; Pyridones; Retrospective Studies; Risk Factors; Tertiary Care Centers; Tomography, X-Ray Computed	2019
Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways. Molecular medicine (Cambridge, Mass.), 2020, 05-24, Volume: 26, Issue:1 Topics: Animals; Cell Survival; Disease Models, Animal; Glycogen Synthase Kinase 3 beta; Humans; Lung; Male; Mice; Pulmonary Fibrosis; Pyridones; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1; Wnt Signaling Pathway	2020
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. Current opinion in pulmonary medicine, 2020, Volume: 26, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Indoles; Lung Diseases, Interstitial; Phenotype; Prognosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Treatment Outcome; Vital Capacity	2020
Lung Myofibroblasts Promote Macrophage Profibrotic Activity through Lactate-induced Histone Lactylation. American journal of respiratory cell and molecular biology, 2021, Volume: 64, Issue:1 Topics: Animals; Cells, Cultured; Histones; Humans; Indoles; Lactates; Lung; Macrophages, Alveolar; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Pulmonary Fibrosis; Pyridones	2021
Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention. Acta pharmacologica Sinica, 2021, Volume: 42, Issue:8 Topics: Acetylcysteine; Convalescence; COVID-19; COVID-19 Drug Treatment; Early Medical Intervention; Glucocorticoids; Humans; Indoles; Pulmonary Fibrosis; Pyridones; SARS-CoV-2	2021
Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton's jelly. Stem cell research & therapy, 2020, 11-30, Volume: 11, Issue:1 Topics: Animals; Bleomycin; Humans; Indoles; Lung; Mesenchymal Stem Cells; Pulmonary Fibrosis; Pyridones; Rats; Wharton Jelly	2020
Pleuroparenchymal fibroelastosis in a patient with systemic sclerosis. Rheumatology (Oxford, England), 2021, 08-02, Volume: 60, Issue:8 Topics: Aged; Bronchiectasis; Disease Progression; Elastic Tissue; Female; Humans; Lung Diseases, Interstitial; Pleural Diseases; Pulmonary Diffusing Capacity; Pulmonary Fibrosis; Pyridones; Scleroderma, Systemic; Tomography, X-Ray Computed; Vital Capacity	2021
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? Cells, 2021, 05-14, Volume: 10, Issue:5 Topics: Biological Factors; COVID-19; COVID-19 Drug Treatment; Humans; Indoles; Lung; Mesenchymal Stem Cells; Pulmonary Fibrosis; Pyridones; SARS-CoV-2	2021
Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience. Respiratory medicine, 2021, Volume: 187 Topics: Aged; Aged, 80 and over; Antifibrotic Agents; Disease Progression; Female; Humans; Incidence; Indoles; Male; Pulmonary Fibrosis; Pyridones; Time Factors; Treatment Outcome	2021
Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. BMC pulmonary medicine, 2017, 04-18, Volume: 17, Issue:1 Topics: Animals; Antioxidants; Basic-Leucine Zipper Transcription Factors; Bleomycin; Bronchoalveolar Lavage Fluid; Collagen Type I; Fibroblasts; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Heme Oxygenase-1; Interleukin-6; Lung; Male; Malondialdehyde; Membrane Proteins; Mice; Mice, Inbred C57BL; Myofibroblasts; NF-E2-Related Factor 2; Oxidative Stress; Pulmonary Fibrosis; Pyridones; RNA, Messenger; Transforming Growth Factor beta	2017
Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world. Respirology (Carlton, Vic.), 2017, Volume: 22, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pulmonary Fibrosis; Pyridones	2017
Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. Respiratory research, 2017, 06-02, Volume: 18, Issue:1 Topics: Animals; Antioxidants; Autophagy; Autophagy-Related Proteins; Bleomycin; Cell Differentiation; Cells, Cultured; Disease Models, Animal; Humans; Lung; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Mitophagy; Myofibroblasts; Oxidative Stress; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pulmonary Fibrosis; Pyridones; Reactive Oxygen Species; Receptors, Platelet-Derived Growth Factor; RNA Interference; Signal Transduction; Transfection; Ubiquitin-Protein Ligases	2017
Unwinding the Collagen Fibrils: Elucidating the Mechanism of Pirfenidone and Nintedanib in Pulmonary Fibrosis. American journal of respiratory cell and molecular biology, 2017, Volume: 57, Issue:1 Topics: Animals; Collagen; Humans; Indoles; Pulmonary Fibrosis; Pyridones	2017
Preference of Aerosolized Pirfenidone to Oral Intake: An Experimental Model of Pulmonary Fibrosis by Paraquat. Journal of aerosol medicine and pulmonary drug delivery, 2018, Volume: 31, Issue:1 Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Male; Oxidative Stress; Paraquat; Pulmonary Fibrosis; Pyridones; Rats; Rats, Sprague-Dawley	2018
Pirfenidone-induced Eosinophilic Pleurisy. Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:14 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Eosinophils; Humans; Male; Pleurisy; Pulmonary Fibrosis; Pyridones; Thoracoscopy	2017
Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis. Inflammation, 2018, Volume: 41, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Cytoprotection; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Glucocorticoids; Hydroxyproline; Inflammation Mediators; Lung; Male; Matrix Metalloproteinase 2; Oxidative Stress; Paraquat; Prednisolone; Pulmonary Fibrosis; Pyridones; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2018
Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2018, Volume: 112 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bronchoalveolar Lavage Fluid; Fibrosis; Gene Expression; Gene Expression Profiling; Herbicides; Hydroxyproline; Lung; Lung Injury; Male; Mice; Organ Size; Oxidative Stress; Paraquat; Pneumonia; Pulmonary Fibrosis; Pyridones; Reactive Oxygen Species; Transforming Growth Factor beta1	2018
Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. International journal of rheumatic diseases, 2018, Volume: 21, Issue:2 Topics: Actins; Adult; Case-Control Studies; Cells, Cultured; Female; Fibroblasts; Fibronectins; Glycogen Synthase Kinase 3 beta; Hedgehog Proteins; Humans; Lung; Lung Diseases, Interstitial; Male; MAP Kinase Kinase 4; Middle Aged; Nuclear Proteins; Patched-1 Receptor; Phosphorylation; Pulmonary Fibrosis; Pyridones; Repressor Proteins; Scleroderma, Systemic; Signal Transduction; Smad2 Protein; Tomography, X-Ray Computed; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2	2018
Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. The European respiratory journal, 2018, Volume: 51, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; France; Greece; Heterozygote; Humans; Male; Middle Aged; Mutation; Patient Safety; Pulmonary Fibrosis; Pyridones; Retrospective Studies; RNA; Spain; Telomerase	2018
Fibrotic microtissue array to predict anti-fibrosis drug efficacy. Nature communications, 2018, 05-25, Volume: 9, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Drug Evaluation, Preclinical; Fibroblasts; Fibrosis; Humans; Indoles; Lung; Lung Compliance; Primary Cell Culture; Pulmonary Fibrosis; Pyridones; Tissue Culture Techniques; Tissue Scaffolds; Treatment Outcome	2018
Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension. The European respiratory journal, 2018, Volume: 52, Issue:2 Topics: Animals; Cell Differentiation; Disease Progression; Female; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Lung; Male; Myofibroblasts; Pulmonary Fibrosis; Pyridones; Pyrimidines; Rats; Rats, Sprague-Dawley; Sulfonamides; Transforming Growth Factor beta1	2018
Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model. Radiation research, 2018, Volume: 190, Issue:4 Topics: Animals; Body Weight; Collagen; Disease Models, Animal; Female; Kaplan-Meier Estimate; Longevity; Lung; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Pyridones; Radiation, Ionizing; Radiotherapy; Signal Transduction; Transforming Growth Factor beta1	2018
Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2018, Volume: 18, Issue:12 Topics: Allografts; Anti-Inflammatory Agents, Non-Steroidal; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Lung Diseases; Lung Transplantation; Male; Middle Aged; Postoperative Complications; Primary Graft Dysfunction; Prognosis; Pulmonary Fibrosis; Pyridones; Retrospective Studies; Risk Factors; Syndrome	2018
Prolonged treatment with open-label pirfenidone in Hermansky-Pudlak syndrome pulmonary fibrosis. Molecular genetics and metabolism, 2018, Volume: 125, Issue:1-2 Topics: Adult; Aged; Female; Hermanski-Pudlak Syndrome; Humans; Lung; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Tomography, X-Ray Computed	2018
Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model. Toxicology letters, 2019, Volume: 300 Topics: Animals; Epithelial-Mesenchymal Transition; Male; Models, Animal; Pulmonary Fibrosis; Pyridones; Rats; Silicon Dioxide; Silicosis	2019
Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients. Oxidative medicine and cellular longevity, 2018, Volume: 2018 Topics: Aged; Antioxidants; Cell Proliferation; Collagen Type I; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pulmonary Fibrosis; Pyridones; Reactive Oxygen Species	2018
Pirfenidone causes false-positive urine benzodiazepine results: Implications for patients with pulmonary fibrosis. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2018, Volume: 37, Issue:12 Topics: Benzodiazepines; Drug Evaluation, Preclinical; False Positive Reactions; Heart Transplantation; Humans; Illicit Drugs; Lung Transplantation; Male; Middle Aged; Preoperative Care; Pulmonary Fibrosis; Pyridones	2018
Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3). International immunopharmacology, 2019, Volume: 74 Topics: Activating Transcription Factor 3; Adult; Aged; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cell Differentiation; Cell Movement; Cells, Cultured; Disease Models, Animal; Down-Regulation; Female; Fibroblasts; Gene Knockdown Techniques; Humans; Lung; Lung Diseases, Interstitial; Male; Mice, Inbred C57BL; Middle Aged; Myofibroblasts; Pulmonary Fibrosis; Pyridones	2019
Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis. Pharmaceutical research, 2013, Volume: 30, Issue:6 Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Chemistry, Pharmaceutical; Dermatitis, Phototoxic; Lung; Male; Pharmaceutical Solutions; Pneumonia; Powders; Pulmonary Fibrosis; Pyridones; Rats; Rats, Sprague-Dawley	2013
Pirfenidone in respirable powder form for the treatment of pulmonary fibrosis: a safer alternative to the current oral delivery system? Therapeutic delivery, 2013, Volume: 4, Issue:8 Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Phototoxic; Humans; Powders; Pulmonary Fibrosis; Pyridones	2013
Pirfenidone: a potential new therapy for restrictive allograft syndrome? American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2013, Volume: 13, Issue:11 Topics: Allografts; Anti-Inflammatory Agents, Non-Steroidal; Emphysema; Fluorodeoxyglucose F18; Humans; Lung Transplantation; Male; Middle Aged; Positron-Emission Tomography; Postoperative Complications; Pulmonary Fibrosis; Pyridones; Radiopharmaceuticals; Syndrome; Tumor Necrosis Factor-alpha	2013
Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respiratory research, 2014, Feb-08, Volume: 15 Topics: Animals; Bleomycin; Cells, Cultured; Female; Fibroblasts; Lung; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Pyridones	2014
Photoallergic contact dermatitis due to treatment of pulmonary fibrosis with pirfenidone. Journal of the European Academy of Dermatology and Venereology : JEADV, 2016, Volume: 30, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Photoallergic; Humans; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Skin; Tumor Necrosis Factor-alpha	2016
A combined therapeutic approach in progressive idiopathic pulmonary fibrosis-pirfenidone as bridge therapy for ex vivo lung transplantation: a case report. Transplantation proceedings, 2015, Volume: 47, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Lung Transplantation; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Quality of Life	2015
[Pulmonary fibrosis]. Medicina clinica, 2016, Feb-05, Volume: 146, Issue:3 Topics: Acetylcysteine; Azathioprine; Clinical Trials as Topic; Forecasting; Glucocorticoids; Humans; Indoles; Multicenter Studies as Topic; Prognosis; Pulmonary Fibrosis; Pyridones	2016
Pulmonary Fibrosis Foundation Summit 2015. The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Clinical Trials as Topic; Congresses as Topic; Drug Approval; Enzyme Inhibitors; Humans; Indoles; Patient Selection; Pulmonary Fibrosis; Pyridones; Rare Diseases	2016
Cutaneous reactions to pirfenidone: a new kid on the block. The British journal of dermatology, 2016, Volume: 175, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Eruptions; Facial Dermatoses; Hand Dermatoses; Humans; Male; Pulmonary Fibrosis; Pyridones; Recurrence	2016
Pirfenidone-induced severe phototoxic reaction in a patient with idiopathic lung fibrosis. Journal of the European Academy of Dermatology and Venereology : JEADV, 2016, Volume: 30, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Sunbathing	2016
MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis. PloS one, 2016, Volume: 11, Issue:5 Topics: A549 Cells; Animals; Bleomycin; Bronchoalveolar Lavage; Cell Line, Tumor; Disease Models, Animal; Epithelial Cells; Female; HeLa Cells; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Injury; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta; Up-Regulation	2016
[111th Scientific Meeting of the Japanese Society of Internal Medicine: Symposium: 3. Fibrosis of the viscera and its treatment; 3). Pulmonary fibrosis and its management]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Sep-10, Volume: 103, Issue:9 Topics: Clinical Trials as Topic; Humans; Lung Volume Measurements; Pulmonary Fibrosis; Pyridones	2014
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production. Blood, 2017, 05-04, Volume: 129, Issue:18 Topics: Allografts; Animals; B-Lymphocytes; Bronchiolitis Obliterans; Chemokine CCL2; Disease Models, Animal; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Interleukin-17; Macrophages; Mice; Mice, Mutant Strains; Pulmonary Fibrosis; Pyridones; Skin Diseases; T-Lymphocytes, Helper-Inducer; Transforming Growth Factor beta	2017
[Salidroside improves pulmonary fibrosis by down-regulation of cathepsin B and NF-κBp65 in rats]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2017, Feb-28, Volume: 42, Issue:2 Topics: Animals; Cathepsin B; Down-Regulation; Glucosides; Lung; NF-kappa B; Oximetry; Oxygen; Phenols; Pulmonary Fibrosis; Pulmonary Gas Exchange; Pyridones; Rats; Rats, Sprague-Dawley	2017
Acoustic evaluation of pirfenidone on patients with combined pulmonary fibrosis emphysema syndrome. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2016, Volume: 2016 Topics: Acoustics; Anti-Inflammatory Agents, Non-Steroidal; Humans; Middle Aged; Pulmonary Emphysema; Pulmonary Fibrosis; Pyridones; Respiratory Sounds; Syndrome; Treatment Outcome	2016
Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. European journal of pharmacology, 2008, Aug-20, Volume: 590, Issue:1-3 Topics: Animals; Bleomycin; Chemokines; Cytokines; Dose-Response Relationship, Drug; Fibroblast Growth Factor 2; Intercellular Signaling Peptides and Proteins; Interferon-gamma; Interleukin-12 Subunit p40; Lung; Male; Mice; Mice, Inbred ICR; Prednisolone; Pulmonary Fibrosis; Pyridones; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2008
Optimal treatment for idiopathic pulmonary fibrosis. Thorax, 2008, Volume: 63, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Pulmonary Fibrosis; Pyridones	2008
Regulatory watch: Surprise setback for lung fibrosis drug highlights trial challenges. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome	2010
[Pirfenidone diminishes SiO2 induced lung fibrosis in rats]. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases, 2010, Volume: 28, Issue:10 Topics: Animals; Hydroxyproline; Lung; Male; Pulmonary Fibrosis; Pyridones; Rats; Rats, Sprague-Dawley; Silicon Dioxide	2010
A rare cause of interstitial lung disease: Hermansky-Pudlak syndrome. Tuberkuloz ve toraks, 2011, Volume: 59, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Dyspnea; Fatal Outcome; Hermanski-Pudlak Syndrome; Humans; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Radiography, Thoracic; Respiratory Insufficiency; Tomography, X-Ray Computed	2011
[The study of effects of pirfenidone on the pulmonary fibrosis induced by paraquat in mice]. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases, 2011, Volume: 29, Issue:2 Topics: Animals; Disease Models, Animal; Lung; Male; Mice; Mice, Inbred ICR; Paraquat; Pulmonary Fibrosis; Pyridones; Transforming Growth Factor beta	2011
Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors. Bioorganic & medicinal chemistry, 2011, Dec-01, Volume: 19, Issue:23 Topics: Administration, Oral; Animals; Azepines; Bleomycin; Disease Models, Animal; Enzyme Inhibitors; Humans; Male; Mice; Mice, Inbred C57BL; NADPH Oxidase 1; NADPH Oxidase 4; NADPH Oxidases; Oxazines; Pulmonary Fibrosis; Pyrazines; Pyridones; Structure-Activity Relationship	2011
Effects of lecithinized superoxide dismutase and/or pirfenidone against bleomycin-induced pulmonary fibrosis. Chest, 2012, Volume: 142, Issue:4 Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Free Radical Scavengers; Lung; Mice; Phosphatidylcholines; Pulmonary Fibrosis; Pyridones; Superoxide Dismutase; Treatment Outcome; Vital Capacity	2012
Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. BMC pulmonary medicine, 2012, Jun-13, Volume: 12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cadherins; Cell Line; Collagen Type I; Epithelial-Mesenchymal Transition; Fibroblasts; Fibronectins; Gene Expression; HSP47 Heat-Shock Proteins; Humans; Lung; Pulmonary Fibrosis; Pyridones; RNA, Messenger; Transforming Growth Factor beta1	2012
Effect of pirfenidone on pulmonary fibrosis due to paraquat poisoning in rats. Clinical toxicology (Philadelphia, Pa.), 2012, Volume: 50, Issue:8 Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Ascorbic Acid; Disease Models, Animal; Herbicides; Injections, Intraperitoneal; Injections, Intravenous; Life Expectancy; Male; Paraquat; Pulmonary Fibrosis; Pyridones; Rats; Rats, Wistar; Survival Rate; Vitamin E	2012
Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology, 2012, Dec-21, Volume: 23, Issue:50 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Bronchoalveolar Lavage; Collagen; Delayed-Action Preparations; Lung; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Polyglactin 910; Pulmonary Fibrosis; Pyridones	2012
From anti-inflammatory drugs through antifibrotic agents to lung transplantation: a long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis. Chest, 2002, Volume: 122, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Clinical Trials as Topic; Forecasting; Humans; Interferon-gamma; Lung Transplantation; Pulmonary Fibrosis; Pyridones; Steroids; Survival Rate; Treatment Outcome	2002
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Internal medicine (Tokyo, Japan), 2002, Volume: 41, Issue:12 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Gas Analysis; Chronic Disease; Feasibility Studies; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Radiography, Thoracic; Respiratory Function Tests; Scleroderma, Systemic; Time Factors; Treatment Outcome	2002
Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicological sciences : an official journal of the Society of Toxicology, 2003, Volume: 75, Issue:1 Topics: Acute Disease; Amiodarone; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cricetinae; Disease Models, Animal; Hydroxyproline; Male; Membrane Potentials; Mitochondria; Oxygen Consumption; Pulmonary Fibrosis; Pyridones; RNA, Messenger; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1	2003
Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. The European respiratory journal, 2004, Volume: 24, Issue:1 Topics: Analysis of Variance; Animals; Biopsy, Needle; Bleomycin; Disease Models, Animal; HSP70 Heat-Shock Proteins; Hydroxyproline; Immunohistochemistry; Injections, Intravenous; Male; Mice; Mice, Inbred Strains; Probability; Pulmonary Fibrosis; Pyridones; Random Allocation; Reference Values; Sensitivity and Specificity	2004
Is idiopathic pulmonary fibrosis now treatable? American journal of respiratory and critical care medicine, 2005, May-01, Volume: 171, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Exercise Test; Humans; Pulmonary Fibrosis; Pyridones; Treatment Outcome	2005
Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2005, Volume: 5, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginase; Arginine; Cells, Cultured; Collagen; Down-Regulation; Gene Expression Regulation; Graft Rejection; Lung Transplantation; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pulmonary Fibrosis; Pyridones; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Signal Transduction; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transplantation, Homologous; Tumor Necrosis Factor-alpha	2005
Sequential testing for efficacy in clinical trials with non-transient effects. Statistics in medicine, 2005, Nov-15, Volume: 24, Issue:21 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Computer Simulation; Data Interpretation, Statistical; Female; Hermanski-Pudlak Syndrome; Humans; Male; Monte Carlo Method; Normal Distribution; Pulmonary Fibrosis; Pyridones; Vital Capacity	2005
Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF. American journal of respiratory and critical care medicine, 2005, Nov-01, Volume: 172, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Exercise Test; Humans; Oxyhemoglobins; Pulmonary Fibrosis; Pyridones; Treatment Outcome	2005
The questionable efficacy of pirfenidone in IPF. American journal of respiratory and critical care medicine, 2005, Nov-01, Volume: 172, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials Data Monitoring Committees; Exercise Test; Humans; Pulmonary Fibrosis; Pyridones; Research Design; Selection Bias; Treatment Outcome	2005
Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis. Archiv der Pharmazie, 2006, Volume: 339, Issue:8 Topics: Administration, Oral; Alanine Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspartate Aminotransferases; Bleomycin; Bronchoalveolar Lavage Fluid; Creatinine; Dihydropyridines; Disease Models, Animal; Hydroxyproline; Intubation, Intratracheal; L-Lactate Dehydrogenase; Lung; Male; Molecular Structure; Pulmonary Fibrosis; Pyridones; Rats; Time Factors; Urea	2006
Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2006, Volume: 21, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Dose-Response Relationship, Drug; Hydroxyproline; Lung; Male; Matrix Metalloproteinase 13; Pulmonary Fibrosis; Pyridones; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1	2006
Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection. Transplantation proceedings, 2007, Volume: 39, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Clinical Trials as Topic; Fibrinolytic Agents; Graft Rejection; Humans; Lung Transplantation; Pulmonary Fibrosis; Pyridones; Reperfusion Injury	2007
Superoxide scavenging activity of pirfenidone-iron complex. Biochemical and biophysical research communications, 2008, Jul-18, Volume: 372, Issue:1 Topics: Cell Line; Free Radical Scavengers; Humans; Iron; Neutrophils; Pulmonary Fibrosis; Pyridones; Superoxides	2008
Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. The Journal of laboratory and clinical medicine, 1995, Volume: 125, Issue:6 Topics: Analysis of Variance; Animals; Bleomycin; Body Weight; Cricetinae; Diet; Hydroxyproline; Lipid Peroxidation; Lung; Male; Mesocricetus; Peroxidase; Procollagen-Proline Dioxygenase; Pulmonary Fibrosis; Pyridones; Superoxide Dismutase	1995
Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicology letters, 1997, Feb-07, Volume: 90, Issue:2-3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclophosphamide; Hydroxyproline; Injections, Intraperitoneal; Male; Mice; Mice, Inbred ICR; Pulmonary Fibrosis; Pyridones	1997
Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1997, Volume: 216, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Body Weight; Cardiovascular System; Cricetinae; Hydroxyproline; Lung; Male; Pulmonary Fibrosis; Pyridones; Respiration; Respiratory Function Tests	1997
Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. The American journal of physiology, 1999, Volume: 276, Issue:2 Topics: 3T3 Cells; Amino Acid Sequence; Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Cricetinae; Isomerism; Kinetics; Lung; Male; Mesocricetus; Mice; Molecular Sequence Data; Platelet-Derived Growth Factor; Protein Biosynthesis; Pulmonary Fibrosis; Pyridones; RNA, Messenger	1999
Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 289, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cricetinae; Gene Expression Regulation; Hydroxyproline; In Situ Hybridization; In Vitro Techniques; Kinetics; Lipid Peroxidation; Lung; Male; Malondialdehyde; Mesocricetus; Procollagen; Procollagen-Proline Dioxygenase; Pulmonary Fibrosis; Pyridones; RNA, Messenger; Transcription, Genetic	1999
Pirfenidone in idiopathic pulmonary fibrosis. Lancet (London, England), 1999, Jul-24, Volume: 354, Issue:9175 Topics: Humans; Pulmonary Fibrosis; Pyridones	1999
Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 291, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Bronchoalveolar Lavage Fluid; Cricetinae; Down-Regulation; Lung; Macrophages; Male; Mesocricetus; Pulmonary Fibrosis; Pyridones; Transcription, Genetic; Transforming Growth Factor beta	1999
Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation, 2000, Volume: 24, Issue:5 Topics: Administration, Oral; Animal Feed; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Bronchoalveolar Lavage Fluid; Capillary Permeability; Cricetinae; Inflammation; Macrophages, Alveolar; Male; Mesocricetus; Neutrophil Infiltration; Pulmonary Fibrosis; Pyridones; Transforming Growth Factor beta	2000